Antibody Induced by Immunization with the Jeryl Lynn Mumps Vaccine Strain Effectively Neutralizes a Heterologous Wild-Type Mumps Virus Associated with a Large Outbreak

Division of Viral Products, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland 20892, USA.
The Journal of Infectious Diseases (Impact Factor: 6). 07/2008; 198(4):508-15. DOI: 10.1086/590115
Source: PubMed


Recent mumps outbreaks in older vaccinated populations were caused primarily by genotype G viruses, which are phylogenetically distinct from the genotype A vaccine strains used in the countries affected by the outbreaks. This finding suggests that genotype A vaccine strains could have reduced efficacy against heterologous mumps viruses. The remote history of vaccination also suggests that waning immunity could have contributed to susceptibility. To examine these issues, we obtained consecutive serum samples from children at different intervals after vaccination and assayed the ability of these samples to neutralize the genotype A Jeryl Lynn mumps virus vaccine strain and a genotype G wild-type virus obtained during the mumps outbreak that occurred in the United States in 2006. Although the geometric mean neutralizing antibody titers against the genotype G virus were approximately one-half the titers measured against the vaccine strain, and although titers to both viruses decreased with time after vaccination, antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralized the outbreak-associated virus at all time points tested.

Download full-text


Available from: William Joseph Bellini, Feb 28, 2015
  • Source
    • "Formerly in Spain the circulating genotype belonged to genotype H1, whereas from 2005 onwards, the circulating genotype belonged to genotype G1, as in the rest of Europe and the United States [29] [30] [31] or to the UK02-19 (a new reference strain for a new genotype)[32]. On the other hand, the vaccine genotype was effective in controlling outbreaks caused by other serotypes and so the role of genotype differences in vaccine failure, if any, is not clear [33] [34]. Besides, in countries with decade-long high immune vaccine coverage , mumps incidence declined more than 99% [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study was to investigate effectiveness of mumps MMR component in communities with high MMR coverage. Outbreak-related cases of mumps born between 1995 and 2005 notified to Navarre and Catalonia public health services during the period 2005-2007 were studied. Vaccine effectiveness (VE) and their 95%CI were calculated using the screening method. Of 47 confirmed, 85.1% immunized with at least one dose (1MMR) and 44.9% with two (2MMR). Estimated VE was 85.4% (95%CI: 67.3-93.4) for 1MMR and 88.5% (95%CI: 78.1-93.9) for 2MMR. High 2MMR coverage, improved confirmation techniques and further VE studies with all confirmed cases are needed to prevent further outbreaks.
    Vaccine 03/2010; 28(20):3567-70. DOI:10.1016/j.vaccine.2010.02.107 · 3.62 Impact Factor
  • Source
    • "All these outbreaks have been due to mumps genotype G viruses. A study from USA showed that although antibody induced by Jeryl Lynn (JL) vaccine strain effectively neutralized genotype G mumps strains, small differences in neutralization titre were observed when sera collected during an outbreak were challenged with wild type genotype G or JL strains (Rubin et al., 2008). These observations have raised public health concerns and suggested that further detailed studies on mumps vaccine efficacy and population susceptibility are warranted. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although the plaque reduction neutralization test (PRNT) is considered the "gold-standard" assay for measuring neutralizing antibodies for mumps, it is technically demanding, slow and requires large serum volumes, which limits its use for investigating mumps vaccine efficacy and population susceptibility. Therefore, an immunocolourimetric-based focus reduction neutralization test (FRNT) was developed and validated against PRNT using 30 blood donor plasma samples (16 positive, 5 equivocal, and 9 negative for mumps IgG by EIA). The samples were tested in triplicate by FRNT and PRNT in 10 and 4 separate assay runs, respectively, and 50% neutralizing antibody titres calculated using the Kärber formula. There was good correlation between the two neutralization assays (R(2)=0.88). Inter-assay variation for FRNT titres was 2-fold, compared to a 3-fold variation for PRNT titres. From the distribution of results, a positive cut-off for FRNT was defined as 1:4. In conclusion, FRNT has similar sensitivity to the PRNT and offers the advantage of speed (2 days vs. 7 days), reduced sample volume (40 microL vs. 150 microL), and the possibility of automation using 96-well plates. FRNT appears to be a good substitute for PRNT for characterising the immune response to mumps and for vaccine efficacy studies.
    Journal of virological methods 09/2009; 163(1):153-6. DOI:10.1016/j.jviromet.2009.09.006 · 1.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In April 1999, a previously healthy 22-year-old woman was taken ill with fever and bilateral swelling of the parotid glands. A chronic course of disease extending from April to December was found with swelling of the parotid glands, fatigue, low grade fever, episodes of tachycardia and nightswetting. Mumps virus RNA of genotype A character based on the SH (small hydrophobic) protein gene classification was demonstrated in three serum samples collected during the course of clinical disease. Different criteria for reinfection were fulfilled including demonstration of IgG antibodies by ELISA in a preinfection serum sample. The preinfection serum sample of the patient was able to efficiently neutralize the infectivity of a heterologous genotype D strain but was unable to neutralize the homologous genotype A virus. The findings in the present study may offer an explanation of a mechanism behind previously observed vaccine failures and the occurrence of reinfection with heterologous mumps virus strains.
    Vaccine 03/2001; 19(13-14):1727-31. DOI:10.1016/S0264-410X(00)00392-3 · 3.62 Impact Factor
Show more